Volume 23 Issue 5
May  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(5): 776-779
DANG Shan, MA Wenjing, CHEN Huixia, SHANG Ruihua, WANG Shulong. Correlation between baseline serum IL-6 levels and cardiovascular and cerebrovascular complications within 3 years in peritoneal dialysis patients[J]. Chinese Journal of General Practice, 2025, 23(5): 776-779. doi: 10.16766/j.cnki.issn.1674-4152.003999
Citation: DANG Shan, MA Wenjing, CHEN Huixia, SHANG Ruihua, WANG Shulong. Correlation between baseline serum IL-6 levels and cardiovascular and cerebrovascular complications within 3 years in peritoneal dialysis patients[J]. Chinese Journal of General Practice, 2025, 23(5): 776-779. doi: 10.16766/j.cnki.issn.1674-4152.003999
shu

Correlation between baseline serum IL-6 levels and cardiovascular and cerebrovascular complications within 3 years in peritoneal dialysis patients

doi: 10.16766/j.cnki.issn.1674-4152.003999
  • 1.

    Department of Renal Rheumatology and Immunology, Central Hospital of Jiaozuo Coal Group, Jiaozuo, Henan 454150, China

Funds:

 LHGJ20210529

  • Received Date: 2024-12-11
    Available Online: 2025-08-14
    Abstract
  •   Objective  To investigate the serum baseline level of IL-6 in peritoneal dialysis patients and assess its potential as a biomarker for predicting the development of cardiovascular and cerebrovascular complications within 3 years.  Methods  A total of 170 patients with end-stage renal disease undergoing peritoneal dialysis and 60 healthy controls in Central Hospital of Jiaozuo Coal Group and the First Affiliated Hospital of Xinxiang Medical University between June 2019 and June 2020 were enrolled in the study. All patients with peritoneal dialysis were followed for 36 months. The patients were divided into the non-cardiovascular and cerebrovascular complications group (n=106) and the cardiovascular and cerebrovascular complications group (n=64). Risk factors for cardiovascular and cerebrovascular complications in peritoneal dialysis patients were analyzed, and the predictive efficacy of IL-6 was analyzed by ROC curve. The relationship between IL-6 expression levels and the median time to onset of cardiovascular and cerebrovascular complications was examined.  Results  The IL-6 expression level was significantly elevated in the peritoneal dialysis group compared to the control group (P < 0.001). In contrast with the non-cardiovascular and cerebrovascular complications group, the serum levels of hypersensitive C-reactive protein, uric acid, TG, TC, LDL-c, and IL-6 were significantly enhanced in the cardiovascular and cerebrovascular complications group (P < 0.05). The hypersensitive C-reactive protein, LDL-c, and IL-6 were identified as independent risk factors for cardiovascular and cerebrovascular complications in patients with peritoneal dialysis. The AUC for baseline serum IL-6 expression level in predicting cardiovascular and cerebrovascular complications in patients with peritoneal dialysis was 0.923, with a sensitivity of 93.25% and specificity of 95.87%. The median time to cardiovascular and cerebrovascular complications onset was shorter in the high IL-6 expression group (16 months) compared to the low IL-6 expression group (27 months, HR=1.688, 95% CI: 1.082-2.293, P < 0.001).  Conclusion  The serum IL-6 can serve as a valuable biomarker for predicting the cardiovascular and cerebrovascular complications in peritoneal dialysis patients.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    NAGAI K, UEDA A. Sustainability of peritoneal dialysis and renal function with proactive combination therapy[J]. J Artif Organs, 2023, 26(4): 335-339.
    [2]
    王超超, 林永强, 陈恬恬, 等. 腹膜透析患者透析液中SGLT1、TGF-α1、VEGF水平与腹膜纤维化的关系及应用价值[J]. 中华全科医学, 2022, 20(2): 251-254. doi: 10.16766/j.cnki.issn.1674-4152.002325

    WANG C C, LIN Y Q, CHEN T T, et al. The correlation between peritoneal fibrosis and the levels of SGLT1, TGF-β1, and VEGF in peritoneal dialysis patients and its application value[J]. Chinese Journal of General Practice, 2022, 20(2): 251-254. doi: 10.16766/j.cnki.issn.1674-4152.002325
    [3]
    成水芹, 周婷婷, 张志宏, 等. 罗沙司他和重组人促红细胞生成素对腹膜透析患者血压及心脑血管并发症的影响[J]. 肾脏病与透析肾移植杂志, 2022, 31(1): 9-14.

    CHENG S Q, ZHOU T T, ZHANG Z H, et al. Roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 2022, 31(1): 9-14.
    [4]
    苏彩虹, 黄丽秋, 李红艳, 等. 腹膜透析患者规律性随访与发生并发症的相关性研究[J]. 国际医药卫生导报, 2022, 28(8): 1057-1061.

    SU C H, HUANG L Q, LI H Y, et al. Correlation between regular follow-up and complications in peritoneal dialysis patients[J]. International Medicine and Health Guidance News, 2022, 28(8): 1057-1061.
    [5]
    郑婕, 罗娟, 彭凤, 等. 腹膜透析患者不同腹膜转运功能与炎症因子、VEGF的相关性研究[J]. 检验医学与临床, 2022, 19(19): 2617-2619.

    ZHENG J, LUO J, PENG F, et al. Study on the correlation between different peritoneal transport functions, inflammatory factors and VEGF in peritoneal dialysis patients[J]. Laboratory Medicine and Clinic, 2022, 19(19): 2617-2619.
    [6]
    徐雪梅, 陈柳, 毛小玲, 等. 影响205例长期维持性腹膜透析患者生存预后的因素分析[J]. 湖南师范大学学报(医学版), 2021, 18(3): 130-133.

    XU X M, CHEN L, MAO X L, et al. Analysis of influencing factors for survival prognosis in 205 patients with continuous ambulatory peritoneal dialysis[J]. Journal of Hunan Normal University (Medical Sciences), 2021, 18(3): 130-133.
    [7]
    WOLTERS T L C, NETEA M G, RIKSEN N P, et al. Acromegaly, inflammation and cardiovascular disease: a review[J]. Rev Endocr Metab Disord, 2020, 21(4): 547-568.
    [8]
    HASSAN M O, DUARTE R, DICKENS C, et al. Interleukin-6 gene polymorhisms and interleukin-6 levels are associated with atherosclerosis in CKD patients[J]. Clin Nephrol, 2020, 93(1): 82-86.
    [9]
    SPENCE J D, URQUHART B L. Cerebrovascular disease, cardiovascular disease, and chronic kidney disease: interplays and influences[J]. Curr Neurol Neurosci Rep, 2022, 22(11): 757-766.
    [10]
    ZOCCALI C, MARK P B, SARAFIDIS P, et al. Diagnosis of cardiovascular disease in patients with chronic kidney disease[J]. Nat Rev Nephrol, 2023, 19(11): 733-746.
    [11]
    杨艳霞, 范宁, 孔玉贤. 新乡市健康体检人群慢性肾脏病患病及知晓情况调查[J]. 华南预防医学, 2023, 49(10): 1318-1321, 1326.

    YANG Y X, FAN N, KONG Y X. The prevalence and awareness of chronic kidney disease among healthy people in Xinxiang City[J]. South China Journal of Preventive Medicine, 2023, 49(10): 1318-1321, 1326.
    [12]
    CHOI Y B, LEE M J, PARK J T, et al. Prognostic value of soluble ST2 and soluble LR11 on mortality and cardiovascular events in peritoneal dialysis patients[J]. BMC Nephrol, 2020, 21(1): 228.
    [13]
    GUO X, ZHU Y, SUN Y, et al. IL-6 accelerates renal fibrosis after acute kidney injury via DNMT1-dependent FOXO3a methylation and activation of Wnt/α-catenin pathway[J]. Int Immunopharmacol, 2022, 109: 108746. DOI: 10.1016/j.intimp.2022.108746.
    [14]
    TYRRELL D J, GOLDSTEIN D R. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6[J]. Nat Rev Cardiol, 2021, 18(1): 58-68.
    [15]
    张薇, 朱冬梅, 唐敏, 等. IL-6和IL-19浓度预测糖尿病肾病患者动脉粥样硬化效果分析[J]. 西部医学, 2021, 33(2): 258-261.

    ZHANG W, ZHU D M, TANG M, et al. Analysis of the effect of IL-6 and IL-19 on the prediction of atherosclerosis in diabetic nephropathy[J]. Medical Journal of West China, 2021, 33(2): 258-261.
    [16]
    王牡丹, 周丽娜, 杨仲煌, 等. 血维生素K2和IL-6水平与慢性肾脏病患者冠状动脉钙化的相关性研究[J]. 中国现代医生, 2023, 61(24): 1-3, 8.

    WANG M D, ZHOU L N, YANG Z H, et al. Correlation of serum vitamin K2 and IL-6 levels with coronary artery calcification in chronic kidney disease patients[J]. China Modern Doctor, 2023, 61(24): 1-3, 8.
    [17]
    BROCH K, ANSTENSRUD A K, WOXHOLT S, et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction[J]. J Am Coll Cardiol, 2021, 77(15): 1845-1855.
    [18]
    BANSHODANI M, KAWANISHI H, MORIISHI M, et al. Association between dialysis modality and cardiovascular diseases: a comparison between peritoneal dialysis and hemodialysis[J]. Blood Purif, 2020, 49(3): 302-309.
    [19]
    CHEN Z, DENG H, SUN K, et al. Prevalence of chronic periodontitis in patients undergoing peritoneal dialysis and its correlation with peritoneal dialysis-related complications[J]. BMC Nephrol, 2023, 24(1): 71.
    [20]
    BATRA G, GHUKASYAN LAKIC T, LINDBǍCK J, et al. Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome[J]. JAMA Cardiol, 2021, 6(12): 1440-1445.
    [21]
    RIDKER P M, DEVALARAJA M, BAERES F M M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial[J]. Lancet, 2021, 397(10289): 2060-2069.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (8) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return